F-star Therapeutics Inc. (FSTX) upgraded Issued by Wall Street Gurus – News Heater
Home  »  Hot Stocks   »  F-star Therapeutics Inc. (FSTX) upgraded Issued by...

F-star Therapeutics Inc. (FSTX) upgraded Issued by Wall Street Gurus

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp

F-star Therapeutics Inc. (NASDAQ:FSTX) went up by 1.87% from its latest closing price compared to the recent 1-year high of $15.50. The company’s stock price has collected -11.53% of loss in the last five trading sessions. Press Release reported on 11/12/21 that F-star Therapeutics to Present at The Society for Immunotherapy of Cancer (SITC) 2021 Conference

Is It Worth Investing in F-star Therapeutics Inc. (NASDAQ :FSTX) Right Now?

Plus, the 36-month beta value for FSTX is at 1.77. Opinions of the stock are interesting as 7 analysts out of 7 who provided ratings for F-star Therapeutics Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


The average price from analysts is $29.67, which is $24.22 above the current price. FSTX currently public float of 20.37M and currently shorts hold a 4.00% ratio of that float. Today, the average trading volume of FSTX was 214.63K shares.

FSTX’s Market Performance

FSTX stocks went down by -11.53% for the week, with a monthly drop of -20.67% and a quarterly performance of -25.65%, while its annual performance rate touched 0.74%. The volatility ratio for the week stands at 9.39% while the volatility levels for the past 30 days are set at 7.41% for F-star Therapeutics Inc.. The simple moving average for the period of the last 20 days is -15.44% for FSTX stocks with a simple moving average of -30.82% for the last 200 days.

Analysts’ Opinion of FSTX

Many brokerage firms have already submitted their reports for FSTX stocks, with Ladenburg Thalmann repeating the rating for FSTX by listing it as a “Buy.” The predicted price for FSTX in the upcoming period, according to Ladenburg Thalmann is $15 based on the research report published on November 18th of the current year 2021.

FSTX Trading at -20.37% from the 50-Day Moving Average

After a stumble in the market that brought FSTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -64.84% of loss for the given period.

Volatility was left at 7.41%, however, over the last 30 days, the volatility rate increased by 9.39%, as shares sank -17.80% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -22.36% lower at present.

During the last 5 trading sessions, FSTX fell by -11.53%, which changed the moving average for the period of 200-days by -49.07% in comparison to the 20-day moving average, which settled at $6.39. In addition, F-star Therapeutics Inc. saw -44.78% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at FSTX starting from Kayitalire Louis, who sale 64 shares at the price of $6.83 back on Nov 02. After this action, Kayitalire Louis now owns 54,255 shares of F-star Therapeutics Inc., valued at $437 using the latest closing price.

Kayitalire Louis, the Chief Medical Officer of F-star Therapeutics Inc., sale 64 shares at $7.23 during a trade that took place back on Oct 04, which means that Kayitalire Louis is holding 54,319 shares at $462 based on the most recent closing price.

Stock Fundamentals for FSTX

Equity return is now at value -68.80, with -51.40 for asset returns.

>> 7 Top Picks for the Post-Pandemic Economy <<

Sign up for our FREE Newsletter and get:

Leave a Comment

Your email address will not be published. Required fields are marked *

Sign up for our FREE Newsletter and get:

Can Amyris Inc. (AMRS) Remain Competitive?

Amyris Inc. (NASDAQ:AMRS) went down by -4.36% from its latest closing price compared to the recent 1-year high of $23.42. The company’s stock price has

Heading

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam

Heading

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam